Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Revlimid Results Rev Up Celgene Corporation (CELG)

Good news seems to find its way to Celgene Corporation (NASDAQ:CELG)‘s door frequently these days. The company announced positive results today from a late-stage study of Revlimid with dexamethasone in treating newly diagnosed multiple myeloma. Shares jumped more than 6% on the news.

Celgene Corporation (NASDAQ:CELG)

FIRST things first
This phase 3 clinical study, called FIRST (for Front-Line Investigation of Revlimid/Dexamethasone vs. Standard Thalidomide), included more than 1,600 patients — making it one of the largest studies ever conducted for newly diagnosed multiple myeloma. Some of the patients received Revlimid with low doses of dexamethasone, while other patients received a regimen consisting of melphalan, prednisone and thalidomide, abbreviated as MPT.

Celgene Corporation (NASDAQ:CELG)’s primary endpoint for the study focused on significant improvement in progression-free survival for the group of patients taking the Revlimid combo. Details have not yet been released, but the company said that this primary endpoint was met with statistical significance. No information was shared at this point about the secondary endpoints for the study — overall survival, response rate, quality of life and safety. Celgene Corporation (NASDAQ:CELG) plans to give more details at an upcoming medical conference.

Whatever that additional information may reveal, the results from the FIRST study appear to have been solid. Celgene says it plans to actively pursue discussions with regulatory authorities in the U.S., Europe, and other countries.

Revved up
As the market reaction shows, the FIRST results are clearly great news for Celgene Corporation (NASDAQ:CELG). Revlimid already stands as a leader in second-line treatment of multiple myeloma. Gaining approval for newly diagnosed cases of the disease opens up more potential.

At this point, there don’t appear to be any storm clouds on the horizon for Revlimid. Approval for the new indication should help it compete against Takeda’s Velcade. Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) brought Kyprolis to the market. However, the drug really isn’t a rival for Revlimid right now, since it is only approved as a third-line treatment for multiple myeloma. Kyprolis could pull some sales away from Celgene Corporation (NASDAQ:CELG)’s Pomalyst, but I don’t think there will be a significant impact.

AbbVie Inc (NYSE:ABBV) and Bristol Myers Squibb Co. (NYSE:BMY) are moving ahead with elotuzumab in three different clinical studies. However, one of those is a phase 2 study that will complete in 2015 and would then presumably require a phase 3 study to follow. Another is a phase 3 study that doesn’t finish until 2018. The third phase 3 study is scheduled to complete in early 2014. But it actually involves elotuzumab with Revlimid, so even a success shouldn’t hurt Celgene’s sales.

The announcement today adds to the momentum that Celgene Corporation (NASDAQ:CELG) has built up over the past couple of years. I expect that momentum to continue. Good news seems likely to keep showing up at this biotech’s door for the foreseeable future.

The article Revlimid Results Rev Up Celgene originally appeared on and is written by Keith Speights.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Celgene.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.